Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 27;71(12):2913–2928. doi: 10.1007/s00262-022-03202-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Patient #5, clinical course a Timeline demonstrating initial diagnosis, status of remission and therapeutic interventions. b Leukocytes, thrombocytes and hemoglobin values during clinical course. c Frequencies of blasts, NPM1 and WT1 NCN in bone marrow during clinical course. NPM1 NCN at day + 665 and + 819 were measured from peripheral blood. d Gene mutations at initial diagnosis of AML measured by next-generation-sequencing (54-myeloid-gene panel)